Reunion Neuroscience Stock Price, News & Analysis
Company Description
Reunion Neuroscience (NASDAQ: REUN) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $13.0M.
REUN stock has declined 100.0% over the past year.
This page provides a comprehensive overview of REUN stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Reunion Neuroscience (REUN) stock. Over the past 12 months, the stock has lost 100.0%. At a market capitalization of $13.0M, REUN is classified as a micro-cap stock with approximately 11.7M shares outstanding.
Latest News
Reunion Neuroscience has 10 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 2 with negative movement. Key topics include conferences, clinical trial, fda approval, earnings. View all REUN news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Days to Cover History
REUN Company Profile & Sector Positioning
Reunion Neuroscience (REUN) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing REUN often look at related companies in the same sector, including Biomx Inc (PHGE), Phio Pharmaceuticals Corp (PHIO), ABPRO HLDGS INC (ABP), Imunon Inc (IMNN), and (CYAD). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate REUN's relative position within its industry.